Liraglutide 3 mg (NN8022)

:Obesity
:Phase 3

Liraglutide 3 mg, a once-daily human GLP-1 analogue. Intended, as adjuvant to lifestyle changes (including diet), to offer sustainable weight loss for people with severe obesity, including those at particular risk of developing diabetes.

Company announcements
People with type 2 diabetes achieve 6% weight loss with liraglutide 3 mg in phase 3a obesity trial (18 Mar 2013)
Novo Nordisk increased operating profit by 13% in the first six months of 2011 (04 Aug 2011)
Interim financial report for the period 1 January 2010 to 30 September 2010 (28 Oct 2010)
Read more company announcements

Press releases
New data demonstrate Victoza® (liraglutide) provided superior and sustained blood sugar control and weight reduction compared to Januvia® (sitagliptin) at 52 weeks (26 Jun 2010)
Novo Nordisk partners with international scientific community for Victoza® cardiovascular outcomes trial (06 May 2010)
Read more press releases

Scientific abstracts
Diabetes (2007)
Diabetes Obesity and Metabolism (2008)
Diabetes Obesity and Metabolism (2008)
Read more scientific abstracts

You can search for more clinical trials on http://clinicaltrials.gov
  •